10-Q · May 15, 2025
Bio-Path reported a Q1 2025 net loss of $2.852 million (basic/diluted loss per share $0.40) versus a $3.157 million loss in Q1 2024 (loss per share $4.88), driven by lower operating expenses and a $0.394 million…
Earnings analysis · 10-Q
BPTH earnings analysis
Filed May 20, 2026 · Our reading of the company's report
The latest report
BPTH's latest 10-Q filing reveals a continued struggle with sustaining financial metrics, as the company reported no revenue for the quarters ending March 31 for both 2026 and 2025. Although there was a notable decrease…
Read full summary
BPTH's latest 10-Q filing reveals a continued struggle with sustaining financial metrics, as the company reported no revenue for the quarters ending March 31 for both 2026 and 2025. Although there was a notable decrease in their net loss and expenses, the lack of revenue generation raises significant concerns about future profitability and operational viability.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.03
What stood out
-
Net Loss Reduced
Net loss for Q1 2026 was $0.3M, down from $2.9M in Q1 2025.
-
Decrease in R&D Expenses
Research and development expenses were $0.1M in Q1 2026, down from $2.0M in Q1 2025.
-
Lower G&A Expenses
General and administrative expenses fell to $0.3M in Q1 2026, compared to $1.3M in Q1 2025.
-
Cash Balance Maintained
As of March 31, 2026, cash was $0.1M, unchanged from the previous quarter.
-
Improvement in EPS
Net loss per share improved to $(0.03) in Q1 2026 from $(0.40) in Q1 2025.
-
Operational Pause Noted
The company has implemented an operational pause in June 2025 to conserve capital.
What to watch
-
Dependence on Future Funding
The company’s ability to continue operations is reliant on securing additional funding amidst a cash balance of only $0.1M.
-
Clinical Trials on Hold
All ongoing clinical trials have been paused due to cash flow constraints, potentially delaying product development.
-
Operational Inefficiencies
The furlough of employees may result in reduced operational effectiveness and potential loss of expertise.
Management's outlook
No forward guidance provided regarding revenue expectations.
Earlier filings 4
10-Q · November 14, 2024
Bio-Path reported an improved operating and EPS result in Q3: net loss narrowed to $(2,115) for the quarter (vs. $(3,199) in 2023 Q3) and basic net loss per share improved to $(0.70) (vs. $(6.36)). Operating expense…
10-Q · August 14, 2024
Bio-Path’s Q2 2024 results show material operating improvement driven by lower R&D spend and a large non-cash gain on warrant remeasurement, producing a smaller net loss of $(1,869) for the quarter (net loss per share…
10-Q · August 14, 2023
Bio-Path reported no revenue and a deeper quarterly loss as R&D activity ramped: net loss for the three months ended June 30, 2023 was $4,234 (net loss per share $0.53) versus $3,008 ($0.42) in the prior-year quarter.…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.